Target intelligence / Profile preview

Mutant tumor protein p53 peptide-HLA class I complex (mutant p53-HLA-I)

Target
mutant p53-HLA-I
Molecular classification
Peptide-MHC complex, Antigen, Other
01

Overview

The mutant TP53 peptide-HLA class I complex is a tumor-specific neoantigen presented on the surface of cancer cells. TP53 is the most frequently mutated tumor suppressor gene in human cancers, with missense mutations clustering in the DNA-binding domain (such as the R175H hotspot mutation). Intracellular mutant p53 proteins undergo proteasomal degradation, and the resulting mutant peptides (e.g., HMTEVVRHC from p53 R175H) are transported to the endoplasmic reticulum, loaded onto major histocompatibility complex (MHC) class I molecules (such as HLA-A*02:01), and presented on the cell surface. This complex serves as a highly specific target for cancer immunotherapy, distinguishing malignant cells from healthy cells that present wild-type p53 peptides.

Because mutant p53 is an intracellular protein, it is inaccessible to conventional monoclonal antibodies. However, the presentation of mutant p53 peptides by HLA class I molecules allows the targeting of these intracellular mutations via T-cell receptor (TCR)-engineered T-cell therapies (TCR-T) or TCR-mimic (TCRm) bispecific antibodies. Therapeutic agents under development, such as the bispecific T-cell engager CLSP-1025 and the TCR-T cell therapy NT-175, specifically bind to the mutant p53 peptide-HLA complex to redirect and activate cytotoxic T lymphocytes to lyse tumor cells. Major challenges in targeting this complex include its extremely low density on the cancer cell surface, potential cross-reactivity with wild-type p53, and the restriction of therapies to patients with specific HLA haplotypes.

Other names
Mutant TP53 peptide-HLA class I complexMutant p53 peptide-HLA class I complexMutant p53 peptide-MHC class I complexMutant TP53 peptide-MHC class I complexp53R175H/HLA-A*02:01 complexp53R175H-HLA-A2 complexMutant p53 neoantigen-HLA complexMutant p53 pHLA
02

Mechanism of action

Drugs targeting this complex act by binding specifically to the mutant p53 peptide-HLA class I complex on the tumor cell surface, while ignoring wild-type p53 complexes. Bispecific T-cell engagers (TCEs) or TCR-mimic antibodies simultaneously bind to CD3 on T cells, thereby redirecting and activating cytotoxic T lymphocytes to lyse the tumor cells. Alternatively, TCR-engineered T-cell therapies (TCR-T) utilize genetically modified T cells expressing TCRs specific to this complex to recognize and destroy the cancer cells.

03

Biological functions

Antigen presentationImmune responseT-cell activation
04

Disease associations

CancerSolid tumorHematologic malignancy
05

Safety considerations

Off-target toxicity due to cross-reactivity with wild-type p53Cytokine release syndromeOn-target, off-tumor toxicityLow antigen density on tumor cellsHLA restriction limiting patient eligibilityImmune escape via HLA downregulation or antigen loss
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

TP53 R175H mutationHLA-A*02:01 genotypeHLA-A*02:01 expressionTP53 mutation statusp53 protein expression

Beyond the preview

Go deeper on Mutant tumor protein p53 peptide-HLA class I complex (mutant p53-HLA-I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mutant tumor protein p53 peptide-HLA class I complex (mutant p53-HLA-I).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call